Eribulin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NYE METODER (Norway), among others, recommended or restricted eribulin, while AWMSG (Wales), CIPM (Spain) and PHARMAC (New Zealand) did not recommend it.
The file has been open for more than a decade: 12.8 years separate the first record, 20 Jul 2011 at HAS (France), from the most recent, 22 May 2024 at CIPM (Spain).
SMC (Scotland) changed its position: not recommended on 10 Oct 2011, restricted by 6 Mar 2016, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for eribulin, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 2 of 18 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for eribulin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 18 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess eribulin, on 20 Jul 2011; CIPM (Spain) did not open a file until 22 May 2024 — an unusually long tail of 12.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 10 years in total.
6 of the 9 agencies here assessed eribulin more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for eribulin.
The full ledger for eribulin reads 10 recommended, 5 not recommended, 1 non-submission and 1 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 22 May 2024 | Indicación terapéutica autorizada: Tratamiento de pacientes adultos con cáncer de mama localmente avanzado o metastásico… | not financed by the SNS · art. 92 d | source |
| PHARMAC (New Zealand) | 21 Nov 2023 | Locally advanced or metastatic breast cancer (following progression on chemotherapy) | PTAC advice: Decline | source |
| NYE METODER (Norway) | 29 Aug 2021 | Behandling av voksne pasienter med inoperabel liposarkom som tidligere har fått antracyklinholdig behandling | introduced | source |
| SMC (Scotland) | 9 Sep 2019 | Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. | not recommended | source |
| HAS (France) | 21 Nov 2018 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
13 further decisions for eribulin, across 7 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 18 decisions for eribulin from 9 agencies, 2011 to 2024. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.